Shanghai-based Everest Medicines Ltd. has won exclusive global rights to a set of viral 3C-like (3CL) protease inhibitors from Singapore's national drug discovery platform, the Experimental Drug Development Centre (EDDC), in a deal worth up to $214.5 million.

Shanghai-based Everest Medicines Ltd. has won exclusive global rights to a set of viral 3C-like (3CL) protease inhibitors from Singapore's national drug discovery platform, the Experimental Drug Development Centre (EDDC), in a deal worth up to $214.5 million.